KalVista Pharmaceuticals Interest Expense 2011-2025 | KALV

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense KalVista Pharmaceuticals

2025	2024	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
4.81 M	9.77 M	9.93 M	9.83 M	7.68 M	4.39 M	2.33 M	2.03 M	1.19 M	1.08 M	405 K	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
9.93 M	405 K	4.86 M

Quarterly Interest Expense KalVista Pharmaceuticals

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
2.49 M	818 K	-	-	1.74 M	1.57 M	-	2.32 M	2.62 M	2.4 M	-	4.31 M	3.49 M	3.55 M	-	2.17 M	3.94 M	7.13 M	-	2.92 M	2.19 M	2.19 M	2.93 M	1.73 M	2.32 M	2.32 M	2.09 M	985 K	1.62 M	1.62 M	1.82 M	661 K	867 K	867 K	555 K	546 K	1 K	406 K	88 K	-	95 K	169 K	836 K	-	357 K	83 K	80 K	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
7.13 M	1 K	1.77 M

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
AlloVir ALVR	1.19 M	-	4.14 %	$ 49.1 M	USA
Ascendis Pharma A/S ASND	65.5 M	$ 220.27	4.81 %	$ 5 B	Danmark
Can-Fite BioPharma Ltd. CANF	227 K	$ 0.28	-2.28 %	$ 609 M	Israel
Alterity Therapeutics Limited ATHE	2.28 K	$ 3.3	-3.51 %	$ 7.94 B	Australia
ARCA biopharma ABIO	9 K	-	1052.0 %	$ 415 M	USA
Arbutus Biopharma Corporation ABUS	459 K	$ 4.75	1.61 %	$ 788 M	Canada
Aclaris Therapeutics ACRS	2.95 M	$ 3.26	-3.12 %	$ 252 M	USA
Adaptimmune Therapeutics plc ADAP	-807 K	-	-15.15 %	$ 60.3 M	Britain
Aeglea BioTherapeutics AGLE	-20.7 M	-	-	$ 1.01 B	USA
Albireo Pharma ALBO	3.69 M	-	-0.23 %	$ 916 M	USA
Alpine Immune Sciences ALPN	476 K	-	-	$ 2.17 B	USA
Ampio Pharmaceuticals AMPE	-5.01 K	-	-11.43 %	$ 502 K	USA
Amphastar Pharmaceuticals AMPH	4.08 M	$ 25.27	-2.43 %	$ 1.22 B	USA
Applied Molecular Transport AMTI	-4 K	-	-	$ 10.1 M	USA
Arena Pharmaceuticals ARNA	4.16 M	-	-6.81 %	$ 3.04 B	USA
Athersys ATHX	103 K	-	3.77 %	$ 22.4 M	USA
Acer Therapeutics ACER	432 K	-	2.71 %	$ 14 M	USA
Avenue Therapeutics ATXI	294 K	-	-52.27 %	$ 4.45 M	USA
Axon Enterprise AXON	286 M	$ 566.18	-2.56 %	$ 42.9 B	USA
Aytu BioScience AYTU	-512 K	$ 2.34	2.59 %	$ 14.7 M	USA
Acorda Therapeutics ACOR	31.5 M	-	-24.86 %	$ 820 K	USA
Brickell Biotech BBI	5 K	-	-5.38 %	$ 6.06 M	USA
BeiGene, Ltd. BGNE	-12.6 M	-	0.49 %	$ 251 B	Cayman-islands
Biohaven Pharmaceutical Holding Company Ltd. BHVN	-7.26 M	$ 11.54	0.87 %	$ 746 M	USA
Biogen BIIB	250 M	$ 174.42	1.11 %	$ 25.4 B	USA
BioVie BIVI	4.3 M	$ 1.42	-5.96 %	$ 2.1 M	USA
Abeona Therapeutics ABEO	418 K	$ 5.36	-2.99 %	$ 115 M	USA
Dynavax Technologies Corporation DVAX	293 K	$ 10.85	-0.14 %	$ 1.41 B	USA
ADiTx Therapeutics ADTX	5.84 K	$ 2.3	-3.0 %	$ 30.3 K	USA
Bellicum Pharmaceuticals BLCM	2.66 M	-	-9.72 %	$ 5.89 M	USA
Berkeley Lights BLI	910 K	-	-7.31 %	$ 87 M	USA
Advaxis ADXS	28 K	-	-9.65 %	$ 45.9 M	USA
BioLineRx Ltd. BLRX	9.07 M	$ 3.17	-1.86 %	$ 908 M	Israel
bluebird bio BLUE	16.4 M	-	-	$ 546 M	USA